[go: up one dir, main page]

WO2005055920A3 - Compositions and methods for treatment of psychiatric disorders - Google Patents

Compositions and methods for treatment of psychiatric disorders Download PDF

Info

Publication number
WO2005055920A3
WO2005055920A3 PCT/IL2004/001117 IL2004001117W WO2005055920A3 WO 2005055920 A3 WO2005055920 A3 WO 2005055920A3 IL 2004001117 W IL2004001117 W IL 2004001117W WO 2005055920 A3 WO2005055920 A3 WO 2005055920A3
Authority
WO
WIPO (PCT)
Prior art keywords
dopamine
treatment
cells
psychiatric disorders
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2004/001117
Other languages
French (fr)
Other versions
WO2005055920A2 (en
Inventor
Michal Eisenbach-Schwartz
Jonathan Kipnis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of WO2005055920A2 publication Critical patent/WO2005055920A2/en
Anticipated expiration legal-status Critical
Publication of WO2005055920A3 publication Critical patent/WO2005055920A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An agent selected from: (i) dopamine; (ii) a dopamine precursor: (iii) a dopamine D1-R agonist: (iv) a combination of dopamine and a dopamine precursor; (v) a combination of dopamine, a dopamine precursor or a dopamine D1-R agonist with a dopamine D2-R antagonist; (vi) a modified CNS-peptide; (vii) T cells that have been activated either by a CNS-specific antigen or by a modified CNS-peptide; and (viii) poly-YE, a poly-YE related peptide or polypeptide, can cause down-regulation of the suppressive activity of CD4+CD25+ regulatory T (Treg) cells on CD4+CD25- effector T cells (Teff), modulation of the immune response and/or modulation of autoimmune response, and are useful for treatment of psychiatric disorders.
PCT/IL2004/001117 2003-12-09 2004-12-09 Compositions and methods for treatment of psychiatric disorders Ceased WO2005055920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52777203P 2003-12-09 2003-12-09
US60/527,772 2003-12-09

Publications (2)

Publication Number Publication Date
WO2005055920A2 WO2005055920A2 (en) 2005-06-23
WO2005055920A3 true WO2005055920A3 (en) 2007-03-08

Family

ID=34676776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/001117 Ceased WO2005055920A2 (en) 2003-12-09 2004-12-09 Compositions and methods for treatment of psychiatric disorders

Country Status (1)

Country Link
WO (1) WO2005055920A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US20100272787A1 (en) * 2007-12-21 2010-10-28 Ben Gurion University Of The Negev Amethod of treating neurodegenerative diseases
US20110033488A1 (en) * 2008-04-15 2011-02-10 Yeda Research And Development Co. Ltd. Agents and methods for treatment of anxiety disorders
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284638A (en) * 1978-11-21 1981-08-18 Ciba-Geigy Corporation Pharmaceutical compositions with central depressant and antipsychotic activity having a butyrophenone derivative which is substituted in the 4-position and a C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydro-pyridine
US5597832A (en) * 1993-04-06 1997-01-28 Abbott Laboratories Tetracyclic compounds as dopamine agonists
US20030003082A1 (en) * 2001-06-28 2003-01-02 Michal Eisenbach-Schwartz Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284638A (en) * 1978-11-21 1981-08-18 Ciba-Geigy Corporation Pharmaceutical compositions with central depressant and antipsychotic activity having a butyrophenone derivative which is substituted in the 4-position and a C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydro-pyridine
US5597832A (en) * 1993-04-06 1997-01-28 Abbott Laboratories Tetracyclic compounds as dopamine agonists
US20030003082A1 (en) * 2001-06-28 2003-01-02 Michal Eisenbach-Schwartz Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOTO K. ET AL.: "Depression in multiple system atrophy: a case report", PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol. 54, 2000, pages 507 - 511, XP008076875 *
HAUBEN E. ET AL.: "Autoimmune T cells as potential neuroprotective therapy for spinal cord injury", LANCET, vol. 355, 22 January 2000 (2000-01-22), pages 286 - 287, XP004814821 *
HAUBEN E. ET AL.: "Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease", JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 4, August 2001 (2001-08-01), pages 591 - 599, XP003008914 *
KIPNIS J. ET AL.: "Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppres the ability to withstand injury to the central nervous systm", PNAS, vol. 99, no. 24, 2002, pages 15620 - 15625, XP003008915 *
RACETTE B.A.: "levodopa responsive parkinsonism in an adult with Huntington's disease", J. NEUROL. NEUROSURG. PSYCHIATRY, vol. 65, 1998, pages 577 - 579, XP003008913 *
SACKS O.W. ET AL.: "Effects of L-Dopa in patients with dementia", THE LANCET, vol. 295, no. 7658, 1970, pages 1231, XP003008916 *

Also Published As

Publication number Publication date
WO2005055920A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
EP2345671B8 (en) Optimized fc variants and methods for their generation
EP1470146B8 (en) Antibodies against the muc18 antigen
WO2006070286A3 (en) Monoclonal antibodies against nkg2a
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
IL180588A0 (en) Humanized anti-cmet antagonists
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
WO2006007529A3 (en) Immunosuppressive exosomes
IL221366A0 (en) SOLUBLE zB7RI POLYPEPTIDE AND METHOD USING IT
SI1814878T1 (en) Spiro-2, 4-pyrimidinediamine compounds and their uses
TW200510459A (en) RG1 antibodies and uses thereof
WO2004099249A3 (en) Optimized fc variants and methods for their generation
NO20085104L (en) Antagonistic anti-human CD40 monoclonal antibody
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2003072713A3 (en) Use of bcma as an immunoregulatory agent
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
EP1818062A3 (en) An anti HSP90 antibody
DE60134645D1 (en) AMIDINE DERIVATIVES AS SELECTIVE NMDA RECEPTOR ANTAGONISTS
WO2005055920A3 (en) Compositions and methods for treatment of psychiatric disorders
WO2004075863A3 (en) Cxcr3 antagonists
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
HK1046925A1 (en) Mage-a12 antigenic peptides and uses thereof
EP1601687A4 (en) Methods for increasing the proliferation of b cells
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
WO2003091383A3 (en) Epha2 antigen t epitopes
WO2000040722A3 (en) Insulin-synthesis genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase